Cargando…

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates

Most triacylglycerol-lowering fibrates have been developed in the 1960s–1980s before their molecular target, peroxisome proliferator-activated receptor alpha (PPARα), was identified. Twenty-one ligand-bound PPARα structures have been deposited in the Protein Data Bank since 2001; however, binding mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamata, Shotaro, Oyama, Takuji, Saito, Kenta, Honda, Akihiro, Yamamoto, Yume, Suda, Keisuke, Ishikawa, Ryo, Itoh, Toshimasa, Watanabe, Yasuo, Shibata, Takahiro, Uchida, Koji, Suematsu, Makoto, Ishii, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653058/
https://www.ncbi.nlm.nih.gov/pubmed/33205029
http://dx.doi.org/10.1016/j.isci.2020.101727
Descripción
Sumario:Most triacylglycerol-lowering fibrates have been developed in the 1960s–1980s before their molecular target, peroxisome proliferator-activated receptor alpha (PPARα), was identified. Twenty-one ligand-bound PPARα structures have been deposited in the Protein Data Bank since 2001; however, binding modes of fibrates and physiological ligands remain unknown. Here we show thirty-four X-ray crystallographic structures of the PPARα ligand-binding domain, which are composed of a “Center” and four “Arm” regions, in complexes with five endogenous fatty acids, six fibrates in clinical use, and six synthetic PPARα agonists. High-resolution structural analyses, in combination with coactivator recruitment and thermostability assays, demonstrate that stearic and palmitic acids are presumably physiological ligands; coordination to Arm III is important for high PPARα potency/selectivity of pemafibrate and GW7647; and agonistic activities of four fibrates are enhanced by the partial agonist GW9662. These results renew our understanding of PPARα ligand recognition and contribute to the molecular design of next-generation PPAR-targeted drugs.